Development of the PARP inhibitor olaparib to generate new therapies for cancer patients

被引：0
|
作者：
O'Connor, Mark J. [1 ]
机构：
[1] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England
来源：
MUTAGENESIS | 2012年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
32
引用
收藏
页码：799 / 799
页数：1
相关论文
共 50 条
  • [31] Discovery of a potent olaparib-chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
    Qin, Hongyu
    Zhang, Jian
    Zhao, Yilu
    Zhang, Lihui
    Feng, Jinhong
    Zhang, Lei
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 13
  • [32] JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib
    Yang, Xueli
    Ndawula, Charles, Jr.
    Zhou, Haiyan
    Gong, Xiaohai
    Jin, Jian
    [J]. ONCOLOGY LETTERS, 2015, 9 (02) : 757 - 761
  • [33] Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
    Gross, Maya
    Spencer, Ryan J.
    [J]. CASE REPORTS IN OBSTETRICS AND GYNECOLOGY, 2022, 2022
  • [34] SYNERGISTIC INTERACTION BETWEEM OLAPARIB, A PARP INHIBITOR, AND CYTOTOXIC AGENT IN TRIPLE NEGATIVE BREAST CANCER
    Hashimoto, J.
    Kitamura, Y.
    Takashima, Y.
    Kodera, Y.
    Shimma, S.
    Hamada, A.
    Fujiwara, Y.
    Koizumi, F.
    Tamura, K.
    [J]. ANNALS OF ONCOLOGY, 2013, 24
  • [35] PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
    Liu, Chuan
    Gross, Neil
    Li, Yanshi
    Li, Guojun
    Wang, Zhihai
    Zhong, Shixun
    Li, Yuncheng
    Hu, Guohua
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (04) : 2444 - 2450
  • [36] The PARP inhibitor olaparib (AZD2281) as potent radiosensitizer of head and neck cancer cells
    Tinhofer, Inge
    Boyko-Fabian, Mariya
    Niehr, Franziska
    Keilholz, Ulrich
    Budach, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] THE ANTITUMOR EFFECT OF TALAPORFIN PHOTO DYNAMICTHERAPY (PDT) COMBINED WITH THE PARP INHIBITOR OLAPARIB FOR GASTRIC CANCER
    Tanaka, Mamoru
    Suzuki, Taketo
    Ichikawa, Hiroshi
    Nishie, Hirotada
    Kataoka, Hiromi
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S311 - S311
  • [38] The PARP inhibitor olaparib (AZD2281) as potent radiosensitizer of head and neck cancer cells
    Tinhofer, I
    Boyko-Fabian, M.
    Niehr, F.
    Keilholz, U.
    Budach, V
    [J]. ONKOLOGIE, 2012, 35 : 194 - 195
  • [39] Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor- Resistant Homologous Recombination-Deficient Ovarian Cancer
    Wethington, Stephanie L.
    Shah, Payal D.
    Martin, Lainie
    Tanyi, Janos L.
    Latif, Nawar
    Morgan, Mark
    Torigian, Drew A.
    Rodriguez, Diego
    Smith, Simon A.
    Dean, Emma
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Ie-Ming
    Brown, Eric J.
    Hwang, Wei -Ting
    Armstrong, Deborah K.
    Gaillard, Stephanie
    Giuntoli, Robert
    Simpkins, Fiona
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (15) : 2800 - 2807
  • [40] PARP-Inhibitor Olaparib in the Treatment of Ovarian Clear Cell Cancer: Predictors of Sensitivity and Resistance
    Dedes, K. J.
    Wilkerson, P.
    Wetterskog, D.
    Lambros, M. B.
    Natrajan, R.
    Tan, D. S.
    Campion-Flora, A.
    Rodrigues, D. N.
    Gauthier, A.
    Daley, F.
    Lord, C. J.
    Kaye, S. B.
    Ashworth, A.
    Reis-Filho, J. S.
    [J]. MODERN PATHOLOGY, 2012, 25 : 265A - 265A
12345